TrialClinical cancer research : an official journal of the American Association for Cancer Research2008

Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Olatoyosi M Odenike et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.